Dr. John William McGillicuddy, MD

Dr. McGillicuddy practices at MUSC Physicians in Mount Pleasant, South Carolina.

Dr. McGillicuddy's NPI, 1528283488, was assigned on April 16, 2007. Dr. McGillicuddy graduated from University of Michigan Medical School in 1998. Dr. McGillicuddy holds South Carolina license 27803.

Dr. McGillicuddy's primary practice is MUSC Physicians, at 1208 2 Island Ct, Mount Pleasant, SC 29466 in Charleston County. The practice phone is (803) 286-4666.

Dr. McGillicuddy's primary practice is MUSC Physicians in Mount Pleasant, South Carolina. Dr. McGillicuddy is also affiliated with MUSC Health University Medical Center. The medical group on file is MUSC Health. Dmand AI also links Dr. McGillicuddy to 2 more group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. McGillicuddy practices, 3 sites in all. Vendor and product names are available with a free account.

Surgery is Dr. McGillicuddy's primary specialty in the NPI Registry, under taxonomy code 208600000X. Dmand AI has Dr. McGillicuddy's licenses on file in 2 states: South Carolina and Michigan.

CMS data shows 47 Medicare services from Dr. McGillicuddy across 3 procedure codes in 2024, for 83 Medicare patients. Medicare paid $12,105 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 83 Medicare patients who saw Dr. McGillicuddy in 2024. The largest group is 65 to 74, with 35 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 34% are also on Medicaid. Their average risk score is 5.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. McGillicuddy's median patient age at 60, with 43% women.

In 2024, Dr. McGillicuddy wrote 804 Medicare Part D claims for 124 patients. 92% of them were for generic drugs. CMS names the drug for 576 of them, across 15 drugs with 11 or more claims each, at $45,628 in total drug cost. In 2023, CMS named 556 claims across 16 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 79 out of 100 for Dr. McGillicuddy for performance year 2024, reported as part of a group. Dr. McGillicuddy accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 23 procedures of spinal fusion by Dr. McGillicuddy, more than 39% of the clinicians it reports for that procedure.

Hernia repair - groin (open): 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 72 papers to Dr. McGillicuddy, published from 2012 to 2022. 2013 was the busiest year, with 9. The most frequent topics are Kidney Transplantation, Immunosuppressive Agents and Graft Rejection. Dr. McGillicuddy has published most often in Clin Transplant. Dr. McGillicuddy's most frequent co-authors are Prabhakar Baliga, MD, Kenneth David Chavin, MD, PhD and Charles Fitzgerald Bratton, MD.

Dmand AI links Dr. McGillicuddy to 1 clinical trial. Conditions studied include Medication Adherence and Patient Compliance.

CMS Open Payments shows 26 general payments to Dr. McGillicuddy from 12 drug and device companies from 2018 to 2025. Food and beverage make up the largest share, 81% of the total. Covidien LP paid the most, $397.

Dr. McGillicuddy graduated from University of Michigan Medical School in 1998.